Shares of Selecta Biosciences Inc (NASDAQ:SELB) have received an average broker rating score of 1.33 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and two have given a strong buy rating to the company.

Brokers have set a 1 year consensus price target of $23.67 for the company and are forecasting that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also given Selecta Biosciences an industry rank of 102 out of 265 based on the ratings given to its competitors.

Several research analysts have issued reports on the company. Zacks Investment Research raised Selecta Biosciences from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Tuesday. Needham & Company LLC assumed coverage on Selecta Biosciences in a research report on Monday, July 18th. They issued a “buy” rating and a $28.00 target price on the stock. Canaccord Genuity assumed coverage on Selecta Biosciences in a research report on Monday, July 18th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on Selecta Biosciences in a research report on Monday, July 18th. They issued a “buy” rating and a $23.00 target price on the stock.

Selecta Biosciences (NASDAQ:SELB) opened at 14.43 on Monday. The company has a 50-day moving average of $12.46 and a 200-day moving average of $12.91. Selecta Biosciences has a one year low of $10.26 and a one year high of $16.32.

In other Selecta Biosciences news, Director Amir Nashat bought 150,000 shares of the firm’s stock in a transaction that occurred on Monday, June 27th. The shares were bought at an average price of $14.00 per share, with a total value of $2,100,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Nanodimension Management Ltd bought 385,000 shares of the firm’s stock in a transaction that occurred on Monday, June 27th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $5,390,000.00. The disclosure for this purchase can be found here.

A number of hedge funds have recently modified their holdings of SELB. Monashee Investment Management LLC acquired a new stake in shares of Selecta Biosciences during the second quarter valued at about $350,000. Laurion Capital Management LP acquired a new stake in shares of Selecta Biosciences during the second quarter valued at about $350,000. Marshall Wace LLP acquired a new stake in shares of Selecta Biosciences during the second quarter valued at about $506,000. Vanguard Group Inc. acquired a new stake in shares of Selecta Biosciences during the second quarter valued at about $1,679,000. Finally, FMR LLC acquired a new stake in shares of Selecta Biosciences during the second quarter valued at about $3,997,000.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.

5 Day Chart for NASDAQ:SELB

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Selecta Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.